1. Market Research
  2. > Healthcare Market Trends
  3. > Generics in Indonesia

Generics in Indonesia

  • January 2017
  • -
  • MarketLine
  • -
  • 32 pages

Summary
Generics in Indonesia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Indonesia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Indonesia
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Indonesia generics market with five year forecasts by both value and volume

Synopsis
Essential resource for top-line data and analysis covering the Indonesia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
- What was the size of the Indonesia generics market by value in 2016?
- What will be the size of the Indonesia generics market in 2021?
- What factors are affecting the strength of competition in the Indonesia generics market?
- How has the market performed over the last five years?
- How large is Indonesia's generics market in relation to its regional counterparts?

Key Findings
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Indonesian generics market is expected to generate total revenues of $911m in 2016, representing a compound annual growth rate (CAGR) of 15.9% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 2.1% between 2012 and 2016, to reach a total of 47.5% of total pharma volume in 2016.

The Indonesian market should continue to see strong growth as the country's first compulsory national health insurance system, which aims to make basic care available to every citizen by 2019, was launched in January 2014.

Table Of Contents

Generics in Indonesia
Table of Contents
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
PT Kalbe Farma Tbk
PT Indofarma (Persero), Tbk
PT Sanbe Farma
PT Soho Global Health
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: Indonesia generics market value: $ billion, 2012-16(e)
Table 2: Indonesia generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Indonesia generics market geography segmentation: $ billion, 2016(e)
Table 4: Indonesia generics market value forecast: $ billion, 2016-21
Table 5: Indonesia generics market volume forecast: % of total pharma volume, 2016-21
Table 6: PT Kalbe Farma Tbk: key facts
Table 7: PT Kalbe Farma Tbk: key financials ($)
Table 8: PT Kalbe Farma Tbk: key financials (IDR)
Table 9: PT Kalbe Farma Tbk: key financial ratios
Table 10: PT Indofarma (Persero), Tbk: key facts
Table 11: PT Indofarma (Persero), Tbk: key financials ($)
Table 12: PT Indofarma (Persero), Tbk: key financials (IDR)
Table 13: PT Indofarma (Persero), Tbk: key financial ratios
Table 14: PT Sanbe Farma: key facts
Table 15: PT Soho Global Health: key facts
Table 16: Indonesia size of population (million), 2012-16
Table 17: Indonesia gdp (constant 2005 prices, $ billion), 2012-16
Table 18: Indonesia gdp (current prices, $ billion), 2012-16
Table 19: Indonesia inflation, 2012-16
Table 20: Indonesia consumer price index (absolute), 2012-16
Table 21: Indonesia exchange rate, 2012-16

List of Figures
Figure 1: Indonesia generics market value: $ billion, 2012-16(e)
Figure 2: Indonesia generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Indonesia generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Indonesia generics market value forecast: $ billion, 2016-21
Figure 5: Indonesia generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Indonesia, 2016
Figure 7: Drivers of buyer power in the generics market in Indonesia, 2016
Figure 8: Drivers of supplier power in the generics market in Indonesia, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Indonesia, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Indonesia, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Indonesia, 2016
Figure 12: PT Kalbe Farma Tbk: revenues and profitability
Figure 13: PT Kalbe Farma Tbk: assets and liabilities
Figure 14: PT Indofarma (Persero), Tbk: revenues and profitability

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Canada Ophthalmic Devices Market Outlook to 2022 - Cataract Surgery Devices, Intraocular Lens (IOL), Vitreo Retinal Surgery Devices, Glaucoma Surgery Devices, Ophthalmic Lasers, Ophthalmic Diagnostic Equipment and Vision Care

Canada Ophthalmic Devices Market Outlook to 2022 - Cataract Surgery Devices, Intraocular Lens (IOL), Vitreo Retinal Surgery Devices, Glaucoma Surgery Devices, Ophthalmic Lasers, Ophthalmic Diagnostic Equipment and Vision Care

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

Canada Ophthalmic Devices Market Outlook to 2022 - Cataract Surgery Devices, Intraocular Lens (IOL), Vitreo Retinal Surgery Devices, Glaucoma Surgery Devices, Ophthalmic Lasers, Ophthalmic Diagnostic Equipment ...

Mexico Ophthalmic Devices Market Outlook to 2022 - Cataract Surgery Devices, Intraocular Lens (IOL), Vitreo Retinal Surgery Devices, Glaucoma Surgery Devices, Ophthalmic Lasers, Ophthalmic Diagnostic Equipment and Vision Care

Mexico Ophthalmic Devices Market Outlook to 2022 - Cataract Surgery Devices, Intraocular Lens (IOL), Vitreo Retinal Surgery Devices, Glaucoma Surgery Devices, Ophthalmic Lasers, Ophthalmic Diagnostic Equipment and Vision Care

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

Mexico Ophthalmic Devices Market Outlook to 2022 - Cataract Surgery Devices, Intraocular Lens (IOL), Vitreo Retinal Surgery Devices, Glaucoma Surgery Devices, Ophthalmic Lasers, Ophthalmic Diagnostic Equipment ...


Download Unlimited Documents from Trusted Public Sources

Blood Disease Statistics in the US

  • February 2017
    24 pages
  • Blood Disease  

    Hospital  

    Intensive Care  

  • United States  

View report >

Healthcare Industry in India - Forecast

  • February 2017
    8 pages
  • Healthcare  

    Hospital  

  • India  

    Asia  

View report >

Heart Failure Statistics in the UK - Forecast

  • February 2017
    8 pages
  • Heart Failure  

    Cardiovascular ...  

  • United Kingdom  

View report >

Related Market Segments :

Pharmaceutical

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.